Results 71 to 80 of about 5,502 (184)

Platelet aggregation inhibition by Eptifibatide versus high dose Tirofiban during primary percutaneous interventions

The Egyptian Heart Journal, 2014
Background: Platelet aggregation occurs as a central role in acute coronary syndrome (ACS), and glycoprotein GP IIb/IIIa inhibitors may enhance the benefits expected from early recanalisation. Aim: To compare the degree of platelet aggregation inhibition
Yasser Sadek Nassar, Mohamed Laimud, Mohamed Afify, Mohamed Ashraf Shawky   +3 more
doaj   +1 more source

Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses. [PDF]

PLoS ONE, 2014
The mainstay of treatment for thrombosis, the formation of occlusive platelet aggregates that often lead to heart attack and stroke, is antiplatelet therapy. Antiplatelet therapy dosing and resistance are poorly understood, leading to potential incorrect
Melissa Li, Nathan A Hotaling, David N Ku, Craig R Forest   +3 more
doaj   +1 more source

Association of Anaesthetists guidelines: the use of blood components and their alternatives

Anaesthesia, Volume 80, Issue 4, Page 425-447, April 2025.
Summary Background The administration of blood components and their alternatives can be lifesaving. Anaemia, bleeding and transfusion are all associated with poor peri‐operative outcomes. Considerable changes in the approaches to optimal use of blood components and their alternatives, driven by the findings of large randomised controlled trials and ...
Akshay Shah, Andrew A. Klein, Seema Agarwal, Andrew Lindley, Aamer Ahmed, Kerry Dowling, Emma Jackson, Sumit Das, Divya Raviraj, Rachel Collis, Anna Sharrock, Simon J. Stanworth, Paul Moor   +12 more
wiley   +1 more source

Platelets induce apoptosis during sepsis in a contact-dependent manner that is inhibited by GPIIb/IIIa blockade. [PDF]

PLoS ONE, 2012
PurposeEnd-organ apoptosis is well-described in progressive sepsis and Multiple Organ Dysfunction Syndrome (MODS), especially where platelets accumulate (e.g. spleen and lung).
Matthew Sharron, Claire E Hoptay, Andrew A Wiles, Lindsay M Garvin, Mayya Geha, Angela S Benton, Kanneboyina Nagaraju, Robert J Freishtat   +7 more
doaj   +1 more source

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction

Journal of Tehran University Heart Center, 2015
Background: Administration of glycoprotein IIb/IIIa inhibitors is an effective adjunctive treatment strategy during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
MohammadHasan Namazi, Morteza Safi, Hosein Vakili, Habibollah Saadat, Esfandiar Karimi, Ramin Khameneh-Bagheri   +5 more
doaj  

Impact of bridging thrombolysis versus endovascular thrombectomy alone on outcomes in anticoagulated patients with atrial fibrillation and acute ischaemic stroke

European Journal of Neurology, Volume 31, Issue 12, December 2024.
Abstract Background and purpose The impact of bridging thrombolysis prior to endovascular thrombectomy (EVT) compared to EVT alone on intracerebral haemorrhage (ICH), subarachnoid haemorrhage (SAH), and death in anticoagulated atrial fibrillation (AF) patients with acute ischaemic stroke (AIS) is not well defined.
Muath Alobaida, Stephanie L. Harrison, Deirdre A. Lane, Fiona Rowe, Philip Austin, Azmil H. Abdul‐Rahim, Gregory Y. H. Lip   +6 more
wiley   +1 more source

RGD-Modified Nano-Liposomes Encapsulated Eptifibatide with Proper Hemocompatibility and Cytotoxicity Effect

Iranian Journal of Biotechnology, 2019
Background Eptifibatide (Integrilin®) is a hepta-peptide drug which specifically prevents the aggregation of activated platelets. The peptide drugs are encapsulated into nanolipisomes in order to decreasing their side effects and improving their half ...
Hassan Bardania, S. Shojaosadati, F. Kobarfard, D. Morshedi, F. Aliakbari, M. Tahoori, E. Roshani   +6 more
semanticscholar   +1 more source

Before, during, and after: An Argument for Safety and Improved Outcome of Thrombolysis in Acute Ischemic Stroke with Direct Oral Anticoagulant Treatment

Annals of Neurology, Volume 96, Issue 5, Page 871-886, November 2024.
Clinicians fear thrombolysis after direct oral anticoagulant (DOAC) use due to experience with warfarin. In contrast to vitamin K antagonists such as warfarin, DOACs prevent thrombosis by blocking thrombin. Clinical observational data suggest that thrombolysis may be safe in the setting of DOAC use.
Sanaz Monjazeb, Heather V. Chang, Patrick D. Lyden   +2 more
wiley   +1 more source

Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)—a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy

Critical Care, 2019
BackgroundPart of the pathophysiology in septic shock is a progressive activation of the endothelium and platelets leading to widespread microvascular injury with capillary leakage, microthrombi and consumption coagulopathy.
R. Berthelsen, S. Ostrowski, M. Bestle, P. I. Johansson   +3 more
semanticscholar   +1 more source

A critical review of therapeutic interventions in sickle cell disease: Progress and challenges

Archiv der Pharmazie, Volume 357, Issue 11, November 2024.
Sickle cell disease reflects a complex interplay of genetics, hematology, and clinical symptoms. The intricate pathogenesis of the disease offers a landscape with various targets and treatment options. Anticipated advancements in treatment include combining fetal hemoglobin inducers with other drug classes to improve the efficacy beyond monotherapy ...
Chandu Ala, Renuka Parshuram Joshi, Pragya Gupta, Sangam Giri Goswami, Sivaprakash Ramalingam, Chandra Sekhar Kondapalli Venkata Gowri, Murugesan Sankaranarayanan   +6 more
wiley   +1 more source